The effect of pranlukast on alveolar exhaled nitric oxide in patients with asthma under inhaled corticosteroid therapy; Open-labeled, cross-over trial.
Not Applicable
- Conditions
- Bronchial Asthma
- Registration Number
- JPRN-UMIN000003781
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
The addition of oral pranlukast to ICS or ICS + LABA therapy may improve asthma control with reducing distal airway inflammation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criterias are as follows. 1. Patients during asthmatic attack,or infectious disease to treat with priority. 2. Patients with history of hypersensitivity to pranlukast. 3. Patients with complications as pneumothorax or severe heart failure. 4. Judgement of attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exhaled nitric oxide (bronchial NO flux and alveolar NO concentration) Plumonary function test (FEV1.0, V50, V25)
- Secondary Outcome Measures
Name Time Method Peak Expiratory Flow Ratio Asthma Control Test (ACT)